Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC
December 19th 2023The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Clinician Insights on the Treatment of Patients With CRC
December 12th 2023The panel reviews treatment strategies for HER2-positive metastatic colorectal cancer patients in various scenarios, including those with HER2 mutations, RAS mutations, and different levels of HER2 expression, emphasizing the importance of reprofiling and considering the duration of response before changing treatment approaches.
Managing Interstitial Lung Disease in Patients With HER2+ mCRC Receiving Trastuzumab Deruxtecan
December 12th 2023Experts explore the management of interstitial lung disease in patients with colorectal cancer receiving treatment with trastuzumab deruxtecan and the consideration of liquid biopsies to assess HER2 status and adapt treatment strategies.
Trastuzumab Deruxtecan in Patients with HER2+ mCRC: The DESTINY-CRC01 Trial
December 5th 2023Dr Stacy A. Cohen discusses the DESTINY-CRC01 trial investigating trastuzumab deruxtecan in patients with colorectal cancer, specifically addressing the use of a targeted therapy for HER2 in colorectal cancer patients, highlighting the importance of prior therapy history and optimal dosage to balance efficacy and toxicity.
MOUNAINEER-03: Tucatinib in Combination with Trastuzumab and Chemotherapy in Patients With HER2+ CRC
November 28th 2023Kristen K. Ciombor, MD, discussed the ongoing MOUNTAINEER-03 trial, a global Phase 3 study randomizing patients with untreated HER2-positive colorectal cancer patients to FOLFOX plus tucatinib/trastuzumab versus standard chemotherapy plus a biologic, which she said highlights the importance of upfront molecular testing and could change treatment.
Strategies for Adverse Event Management in Patients With CRC Receiving Tucatinib
November 28th 2023Toxicities with tucatinib in patients with colorectal cancer like fatigue and GI issues are generally manageable but still require close monitoring, with early optimization of diarrhea management being key to allow patients to stay on effective treatment long-term.
Tucatinib in Patients With CRC: Data From MOUNTAINEER-01
November 21st 2023In the Phase 2 MOUNTAINEER-01 study of patients with HER2-positive metastatic colorectal cancer who were chemo-refractory, the combination of tucatinib and trastuzumab showed an impressive response rate and disease control rate, and median duration of response up to 12 months; Dr. Ahn notes these results compare favorably to prior studies of dual HER2 inhibition, with MOUNTAINEER-01 showing higher response rates.
Overview of Colorectal Cancer (CRC)
November 7th 2023Stacy A. Cohen, MD, provides an overview of colorectal cancer, noting increasing incidence in younger patients; Christina S. Wu, MB, BCh, MD, discussed possible reasons for more colorectal cancer in younger people, including genetic predisposition and exposures, though the causes remain unclear.